Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Eastern Cooperative Oncology Group
Emory University
NRG Oncology
Eastern Cooperative Oncology Group
NRG Oncology
Boehringer Ingelheim
University of California, San Diego
Emory University
National Cancer Institute (NCI)
NRG Oncology
Tanabe Pharma America, Inc.
TScan Therapeutics, Inc.
Mayo Clinic
Cedars-Sinai Medical Center
M.D. Anderson Cancer Center
University of Kentucky
Sichuan Baili Pharmaceutical Co., Ltd.
Travera Inc
University of California, San Diego
Turning Point Therapeutics, Inc.
Marengo Therapeutics, Inc.
Hoffmann-La Roche
Numab Therapeutics AG
Regeneron Pharmaceuticals
Emory University
Eurofarma Laboratorios S.A.
Intensity Therapeutics, Inc.
University of Utah
University of California, San Francisco
Vaccinex Inc.
National Cancer Institute (NCI)
Travera Inc
Helsinki University Central Hospital
Simcha IL-18, Inc.
Atara Biotherapeutics
UNICANCER
Dyameo
Cancer Research UK
Eastern Cooperative Oncology Group
R-Pharm
Ohio State University Comprehensive Cancer Center
Evopoint Biosciences Inc.